Literature DB >> 18240296

Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation.

Beate Köberle1, Vera Roginskaya, Karen S Zima, John R W Masters, Richard D Wood.   

Abstract

Most testicular germ cell tumors are curable using cisplatin-based chemotherapy, and cell lines from these tumors are unusually sensitive to cisplatin and other DNA-damaging agents. It has been suggested that this might be caused by a lower-than normal nucleotide excision repair (NER) activity. Previous studies found that cell lines from testicular germ cell tumors have on average about one-third the level of the NER protein XPA in comparison to cell lines from other tumors. We asked whether over-expression of XPA protein would alleviate the cellular sensitivity and increase the DNA repair capacity of a testis tumor cell line. Increasing XPA levels in 833K cells by 10-fold did not increase resistance to UV irradiation. XPA was localized to the cell nucleus in all cell lines, before and after exposure to UV-radiation. 833K cells were proficient in removing UV radiation-induced photoproducts from the genome and increased XPA did not enhance the rate of removal. Further, over-expressing functional XPA protein did not correlate with increased resistance of 833K testis tumor cells to cisplatin. Thus, although the amount of XPA in this testis tumor cell line is lower than normal, it is sufficient for NER in vivo. The relative sensitivity of testis tumor cells to cisplatin, UV radiation, and other DNA damaging agents is likely related not to NER capacity, but to other factors such as the integrity of the p53 pathway in these cells. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18240296     DOI: 10.1002/mc.20418

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  13 in total

1.  Testing the metal of ERCC2 in predicting the response to platinum-based therapy.

Authors:  John J Turchi; Derek S Woods; Pamela VanderVere-Carozza
Journal:  Cancer Discov       Date:  2014-10       Impact factor: 39.397

Review 2.  Molecular mechanisms behind the resistance of cisplatin in germ cell tumours.

Authors:  Josep Ma Piulats; Laura Jiménez; Xavier García del Muro; Alberto Villanueva; Francesc Viñals; José R Germà-Lluch
Journal:  Clin Transl Oncol       Date:  2009-12       Impact factor: 3.405

3.  Increased expression of DNA repair gene XPF enhances resistance to hydroxycamptothecin in bladder cancer.

Authors:  Jie Li; Junlei Zhang; Yang Liu; Gang Ye
Journal:  Med Sci Monit       Date:  2012-04

4.  p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin.

Authors:  Matthias Gutekunst; Moshe Oren; Andrea Weilbacher; Michael A Dengler; Christiane Markwardt; Jürgen Thomale; Walter E Aulitzky; Heiko van der Kuip
Journal:  PLoS One       Date:  2011-04-21       Impact factor: 3.240

5.  Regulation of nucleotide excision repair activity by transcriptional and post-transcriptional control of the XPA protein.

Authors:  Tae-Hong Kang; Joyce T Reardon; Aziz Sancar
Journal:  Nucleic Acids Res       Date:  2010-12-30       Impact factor: 16.971

6.  Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.

Authors:  Qi-En Wang; Keisha Milum; Chunhua Han; Yi-Wen Huang; Gulzar Wani; Jürgen Thomale; Altaf A Wani
Journal:  Mol Cancer       Date:  2011-03-08       Impact factor: 27.401

7.  Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.

Authors:  Svetlana Usanova; Andrea Piée-Staffa; Ulrike Sied; Jürgen Thomale; Astrid Schneider; Bernd Kaina; Beate Köberle
Journal:  Mol Cancer       Date:  2010-09-16       Impact factor: 27.401

8.  Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours.

Authors:  J Mendoza; J Martínez; C Hernández; D Pérez-Montiel; C Castro; E Fabián-Morales; M Santibáñez; R González-Barrios; J Díaz-Chávez; M A Andonegui; N Reynoso; L F Oñate; M A Jiménez; M Núñez; R Dyer; L A Herrera
Journal:  Br J Cancer       Date:  2013-06-27       Impact factor: 7.640

9.  High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy.

Authors:  Xiang Fu; Jiali Hu; Hong-yu Han; Yi-jun Hua; Ling Zhou; Wen-di Shuai; Wu-ying Du; Chun-mei Kuang; Shuai Chen; Wenlin Huang; Ran-yi Liu
Journal:  Oncotarget       Date:  2015-09-29

10.  Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer.

Authors:  F Selle; J Gligorov; S Richard; A Khalil; I Alexandre; D Avenin; S Provent; D G Soares; J P Lotz
Journal:  Braz J Med Biol Res       Date:  2014-11-04       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.